AFINITOR is contraindicated in patients with hypersensitivity to everolimus, other rapamycin derivatives, or any excipients.
Noninfectious pneumonitis was reported in up to 19% of patients...
When it Comes to Patient Support—We’ve Got It Covered
We know that our patients need prompt access to affordable medication right from the beginning. That’s why the We’ve Got It Covered Program helps patients get started on the therapy you prescribe and then works to help them stay on it. Whatever the insurance coverage challenge, we’re committed to helping make AFINITOR® (everolimus) Tablets accessible to eligible patients.
Bridging the Gap—With a 14-day Supply
When you first prescribe your patients AFINITOR for any Food and Drug Administration-approved indication, they are eligible for an initial 14-day supply of their medication. This allows eligible patients to get on therapy quickly while our experts assist them with financial or coverage needs. Additionally, if a dose change is necessary, your patients may be eligible for another 14-day supply while we re-secure coverage.
14-Day supply application form and complete terms and conditions can be accessed at www.AFINITOR-NOW.com
Getting Insurance on Board—Right From the Start
Our reimbursement experts assist at every step to help make sure all eligible patients with insurance get the access they need. Our experts are trained in benefits verifications and prior authorization (PA) assistance*. Plus, they’ll also help with many of the possible complications that can arise, including denied or appealed insurance claims.
*PA assistance available to eligible patients.
Universal Co-pay Card Program
Your patient may be eligible for immediate co-pay savings on their next prescription:
To find out if your patient is eligible to save on their next prescription,
call 877-577-7756 or visit us on www.copay.novartisoncology.com.
Limitations apply. See program terms and conditions below. This offer is not valid under
Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to
rescind, revoke, or amend this program without notice.
Terms and Conditions
This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2017.
Patients with commercial insurance will be responsible for up to $25 and the program pays the remaining co-pay or coinsurance until you reach the yearly maximum of $15,000. After the program maximum, you will be responsible for the difference. Questions should be directed to: 877-577-7756. When you use this offer, you are certifying that you understand the program rules, regulations, and terms and conditions, and that you will disclose and report the use of this offer as may be required by your insurer. You are not eligible if prescriptions are paid by any federal or state program, or where prohibited by law; and you will otherwise comply with the terms and conditions above.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors:
Impaired Wound Healing:
Laboratory Tests and Monitoring:
Please see full Prescribing Information.
Abbreviations: aRCC, advanced renal cell carcinoma; mTOR, mammalian target of rapamycin; RCC, renal cell carcinoma; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine inhibitor.
References: 1. Abou Youssif T, Fahmy MA, Koumakpayi IH, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer. 2011;117(2):290-300. 2. AFINITOR [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.